Cancer Cell Patents (Class 424/155.1)
-
Patent number: 7256272Abstract: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells.Type: GrantFiled: November 13, 2003Date of Patent: August 14, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Miyoko Takahashi
-
Patent number: 7253263Abstract: The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives.Type: GrantFiled: September 29, 2000Date of Patent: August 7, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Nobuo Hanai, Kenya Shitara, Kazuyasu Nakamura, Rinpel Niwa
-
Patent number: 7252821Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: June 23, 2003Date of Patent: August 7, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Miyoko Takahashi
-
Patent number: 7252994Abstract: Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.Type: GrantFiled: June 29, 2002Date of Patent: August 7, 2007Assignee: Genentech, Inc.Inventors: Anan Chuntharapai, Kyung Jin Kim
-
Publication number: 20070178107Abstract: The present invention relates to method and means for treating a solid tumor using a number of, in vitro prepared, anticellular agent(s)-carrying blood platelets to induce a thrombus formation within the tumor vasculature, and at the same time to deliver a high concentration of an anticellular agent within the tumor. The blood platelets are targeted and attached to the tumor vasculature using in vivo assembled binding complexes, each having at least one binding site specifically binding to tumor cells or to tumor-associated vasculature, and at least one binding site specifically binding to a blood platelet surface. The platelet-mediated thrombus formed within the tumor vasculature leads to occlusion of the tumor vasculature, with ultimate destruction of the centrally located tumor cells. This is followed by destruction or impairing the growth or cell division of the peripherally located tumor cells, by the anticellular agent(s) carried by the blood platelets.Type: ApplicationFiled: November 10, 2006Publication date: August 2, 2007Inventor: Essam T. Awdalla
-
Patent number: 7241568Abstract: A method for preventing or treating a disease, comprising administering to human or animal in need of such prevention or treatment an effective amount of a monoclonal antibody which specifically binds to FGF-8 and inhibits FGF-8 activity.Type: GrantFiled: May 9, 2003Date of Patent: July 10, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Nobuo Hanai, Motoo Yamasaki, Akiko Furuya, Akira Tanaka, Kenya Shitara, Naoki Shimada, Kazuyasu Nakamura, Maiko Hirota
-
Patent number: 7238785Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: GrantFiled: March 3, 2003Date of Patent: July 3, 2007Assignee: Immunomedics, Inc.Inventors: Serengulam Govindan, Zhengxing Qu, Hans Hansen, David Goldenberg
-
Patent number: 7238786Abstract: This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.Type: GrantFiled: June 16, 2003Date of Patent: July 3, 2007Assignee: Immunomedics, Inc.Inventors: David V. Gold, David M. Goldenberg, Hans J. Hansen
-
Patent number: 7232888Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.Type: GrantFiled: July 1, 2003Date of Patent: June 19, 2007Assignee: Massachusetts Institute of TechnologyInventors: Richard J. H. Begent, Kerry Ann Chester, Christilyn P. Graff, K. Dane Wittrup
-
Patent number: 7226596Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.Type: GrantFiled: August 22, 2002Date of Patent: June 5, 2007Assignee: Genentech, Inc.Inventors: Sarah C. Bodary, Karen L. Fisher
-
Patent number: 7217799Abstract: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.Type: GrantFiled: August 28, 2001Date of Patent: May 15, 2007Assignee: Agensys, Inc.Inventors: Arthur B. Raitano, Mary Faris, Rene S. Hubert, Daniel E. Afar, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
-
Patent number: 7217796Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.Type: GrantFiled: May 22, 2003Date of Patent: May 15, 2007Assignee: Schering CorporationInventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
-
Patent number: 7208151Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: GrantFiled: September 12, 2001Date of Patent: April 24, 2007Assignee: Biogen Idec MA Inc.Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Patent number: 7204982Abstract: The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the brain, lung, breast, prostate and colon. The method comprises contacting a cancer cell with a molecule that disrupts the biological activity of a GDOX molecule. In one embodiment, the molecule is an antibody directed against a GDOX peptide. In other embodiments, the molecule is an antisense nucleotide directed against a GDOX nucleic acid molecule, or a vaccine comprising a GDOX peptide or a polynucleotide encoding a GDOX peptide. The invention additionally provides methods for detecting and treating cancer using GDOX-related molecules.Type: GrantFiled: July 2, 2002Date of Patent: April 17, 2007Assignee: The Regents of the University of CaliforniaInventor: Linda M. Liau
-
Patent number: 7202346Abstract: The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.Type: GrantFiled: July 3, 2003Date of Patent: April 10, 2007Assignee: Immunogen Inc.Inventors: Gillian Payne, Thomas Chittenden, Viktor Goldmakher, Philip Chun, Kristin Sneider-Mulready, Carol A. Vater
-
Patent number: 7198787Abstract: A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above nucleated cells or from bone marrow aspirates, in which method the cell population is in vitro or in vivo exposed to two or more immunotoxins selectively killing the malignant cells, is described. Furthermore the invention relates to the mixture of immunotixins, the use of the mixture and a kit for performing the method.Type: GrantFiled: March 12, 1997Date of Patent: April 3, 2007Assignee: Oystein FodstadInventors: Oystein Fodstad, Gunnar Kvalbeim, Meng yu Wang, Olav Engebraten, Siri Juell
-
Patent number: 7195764Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: September 15, 2004Date of Patent: March 27, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7192585Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (GD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: May 31, 2005Date of Patent: March 20, 2007Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7192586Abstract: Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).Type: GrantFiled: May 30, 2002Date of Patent: March 20, 2007Assignee: Cornell Research Foundation, Inc.Inventor: Neil Bander
-
Patent number: 7189397Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: GrantFiled: August 22, 2003Date of Patent: March 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7189824Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody, pharmaceutical agents comprising the monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of the monoclonal antibody and another conjugating molecule.Type: GrantFiled: November 8, 2001Date of Patent: March 13, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
-
Patent number: 7189825Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: July 15, 2004Date of Patent: March 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7186808Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: July 15, 2004Date of Patent: March 6, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7179899Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: GrantFiled: September 25, 2002Date of Patent: February 20, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan
-
Patent number: 7175846Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: August 3, 2006Date of Patent: February 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7169390Abstract: Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind spingolipids or sphingolipid metabolites. In one embodiment the agent is an antibody or antibody derivative. In some embodiments, the agent is a receptor of a sphingolipid or a sphingolipid metabolite. Also disclosed are methods for identifying and isolating therapeutic agents.Type: GrantFiled: April 7, 2004Date of Patent: January 30, 2007Assignee: Lpath Therapeutics, Inc.Inventor: Roger A. Sabbadini
-
Patent number: 7166286Abstract: The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.Type: GrantFiled: August 29, 2003Date of Patent: January 23, 2007Assignee: Viventia Biotech Inc.Inventors: Michael D. Dan, Pradip K. Maiti, Carol Grad, legal representative, Howard A. Kaplan, deceased
-
Patent number: 7160858Abstract: Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a compound which binds annexin II and a pharmaceutically acceptable vehicle and methods for identifying such compounds.Type: GrantFiled: September 4, 2001Date of Patent: January 9, 2007Assignee: Philadelphia, Health and Education CorporationInventors: Mahesh C. Sharma, George P. Tuszynski
-
Patent number: 7153508Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: February 13, 2002Date of Patent: December 26, 2006Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7150871Abstract: Methods and compositions comprising antagonists of ?v?6 are provided for the treatment of acute lung injury fibrosis.Type: GrantFiled: January 9, 2004Date of Patent: December 19, 2006Assignee: Regents of the University of CaliforniaInventors: Xiaozhu Huang, Dean Sheppard
-
Patent number: 7151169Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: September 13, 2002Date of Patent: December 19, 2006Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 7151164Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.Type: GrantFiled: February 14, 2003Date of Patent: December 19, 2006Assignee: Immunomedics, Inc.Inventors: Hans Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7147855Abstract: The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors. The invention further provides methods for detecting the GIP90/130 polypeptides or nucleic acid sequences, methods for inhibiting interactions between GPBP and GIP90/130 polypeptides, between pol k76 and GIP90/130 polypeptides or aggregation of GIP90/130 polypeptides, and methods for treating patients with autoimmune disorders or cancer.Type: GrantFiled: December 4, 2002Date of Patent: December 12, 2006Inventors: Juan Saus, Francisco Revert-Ros
-
Patent number: 7129332Abstract: The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.Type: GrantFiled: February 23, 2001Date of Patent: October 31, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ira Pastan, Richard Beers, Partha S. Chowdhury, Darell Bigner
-
Patent number: 7125541Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: December 14, 2000Date of Patent: October 24, 2006Assignee: The University of Texas System Board of RegentsInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7115715Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).Type: GrantFiled: September 27, 2001Date of Patent: October 3, 2006Assignee: Institute of Virology Slovak Academy of SciencesInventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 7115717Abstract: Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing human hepatocyte toxicity.Type: GrantFiled: May 17, 2002Date of Patent: October 3, 2006Assignee: Kirin Beer Kabushiki KaishaInventors: Eiji Mori, Shiro Kataoka
-
Patent number: 7115577Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: December 27, 2004Date of Patent: October 3, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Patent number: 7112317Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: February 27, 2003Date of Patent: September 26, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7109306Abstract: The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Antibodies to human HOIPS I are also provided, as are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.Type: GrantFiled: August 3, 2004Date of Patent: September 19, 2006Assignee: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Steven M. Ruben
-
Patent number: 7097840Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.Type: GrantFiled: March 16, 2001Date of Patent: August 29, 2006Assignees: Genentech, Inc., Immunogen, Inc.Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
-
Patent number: 7097836Abstract: The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic agent. The anti-endoglin antibody and the chemotherapeutic agent may be administered sequentially or concurrently.Type: GrantFiled: October 22, 2003Date of Patent: August 29, 2006Assignee: Health Research, Inc.Inventor: Ben K. Seon
-
Patent number: 7094404Abstract: The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.Type: GrantFiled: June 7, 1995Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Thomas A. Waldmann
-
Patent number: 7090844Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: September 10, 2003Date of Patent: August 15, 2006Assignee: Abgenix, Inc.Inventors: Menashe Bar-Eli, Larry L. Green
-
Patent number: 7090843Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: GrantFiled: November 28, 2000Date of Patent: August 15, 2006Assignee: Seattle Genetics, Inc.Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall
-
Patent number: 7081518Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.Type: GrantFiled: May 26, 2000Date of Patent: July 25, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ira Pastan, Partha S. Chowdhury
-
Patent number: 7074404Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.Type: GrantFiled: September 24, 2004Date of Patent: July 11, 2006Assignee: Genentech, Inc.Inventors: Carol D. Basey, Greg S. Blank
-
Patent number: 7074405Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: June 22, 1999Date of Patent: July 11, 2006Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7070778Abstract: The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either ?-(1,3)-glucan like laminarin or a oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.Type: GrantFiled: October 30, 2003Date of Patent: July 4, 2006Assignee: Laboratoire Goemar SAInventors: Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka
-
Patent number: 7067128Abstract: Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.Type: GrantFiled: October 8, 2003Date of Patent: June 27, 2006Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg